|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-27
|
|
pubmed:abstractText |
The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q. We performed a clinical trial to prospectively evaluate the safety of treating patients with AO with temozolomide (TMZ) alone in patients with chromosome 1p/19q loss and with chemo-radiation in patients not harboring this loss. Forty-eight patients were enrolled, 36/48 (75%) with evidence of chromosome 1p/19q loss treated with TMZ alone and 12/18 (25%) without such losses, treated with pre-radiation TMZ followed by chemo-radiation. Despite more aggressive treatment, patients without 1p/19q loss had a shorter progression-free survival (PFS) of 13.5 months. With a median follow-up time of 32 months, patients with 1p/19q LOH had a median TTP of 28.7 months. Patients with AO with 1p/19q LOH can be safely treated with single-agent TMZ and do not appear to experience earlier or more frequent tumor progression. This treatment regimen should be studied as part of a formal randomized clinical trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0167-594X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
57-63
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19011763-Antineoplastic Agents, Alkylating,
pubmed-meshheading:19011763-Brain Neoplasms,
pubmed-meshheading:19011763-Chromosomes, Human, Pair 1,
pubmed-meshheading:19011763-Chromosomes, Human, Pair 19,
pubmed-meshheading:19011763-Combined Modality Therapy,
pubmed-meshheading:19011763-DNA Methylation,
pubmed-meshheading:19011763-DNA Modification Methylases,
pubmed-meshheading:19011763-DNA Repair Enzymes,
pubmed-meshheading:19011763-Dacarbazine,
pubmed-meshheading:19011763-Disease-Free Survival,
pubmed-meshheading:19011763-Humans,
pubmed-meshheading:19011763-Kaplan-Meier Estimate,
pubmed-meshheading:19011763-Loss of Heterozygosity,
pubmed-meshheading:19011763-Oligodendroglioma,
pubmed-meshheading:19011763-Prognosis,
pubmed-meshheading:19011763-Promoter Regions, Genetic,
pubmed-meshheading:19011763-Tumor Suppressor Proteins
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma.
|
|
pubmed:affiliation |
Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA. nstom@neuro.hfh.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II
|
